227 related articles for article (PubMed ID: 25943458)
1. Comparative Pharmacology of Risperidone and Paliperidone.
Corena-McLeod M
Drugs R D; 2015 Jun; 15(2):163-74. PubMed ID: 25943458
[TBL] [Abstract][Full Text] [Related]
2. Signalling profile differences: paliperidone versus risperidone.
Clarke WP; Chavera TA; Silva M; Sullivan LC; Berg KA
Br J Pharmacol; 2013 Oct; 170(3):532-45. PubMed ID: 23826915
[TBL] [Abstract][Full Text] [Related]
3. Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons.
Dremencov E; El Mansari M; Blier P
Psychopharmacology (Berl); 2007 Sep; 194(1):63-72. PubMed ID: 17530476
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats.
Kozielska M; Johnson M; Pilla Reddy V; Vermeulen A; Li C; Grimwood S; de Greef R; Groothuis GM; Danhof M; Proost JH
Pharm Res; 2012 Jul; 29(7):1932-48. PubMed ID: 22437487
[TBL] [Abstract][Full Text] [Related]
5. Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone.
Muly EC; Votaw JR; Ritchie J; Howell LL
J Pharmacol Exp Ther; 2012 Apr; 341(1):81-9. PubMed ID: 22214649
[TBL] [Abstract][Full Text] [Related]
6. New model of action for mood stabilizers: phosphoproteome from rat pre-frontal cortex synaptoneurosomal preparations.
Corena-McLeod M; Walss-Bass C; Oliveros A; Gordillo Villegas A; Ceballos C; Charlesworth CM; Madden B; Linser PJ; Van Ekeris L; Smith K; Richelson E
PLoS One; 2013; 8(5):e52147. PubMed ID: 23690912
[TBL] [Abstract][Full Text] [Related]
7. Physiologically Based Modeling Approach to Predict Dopamine D2 Receptor Occupancy of Antipsychotics in Brain: Translation From Rat to Human.
Wong YC; Centanni M; de Lange ECM
J Clin Pharmacol; 2019 May; 59(5):731-747. PubMed ID: 30676661
[TBL] [Abstract][Full Text] [Related]
8. The preclinical discovery and development of paliperidone for the treatment of schizophrenia.
Wesołowska A; Jastrzębska-Więsek M; Cios A; Partyka A
Expert Opin Drug Discov; 2020 Mar; 15(3):279-292. PubMed ID: 31661992
[No Abstract] [Full Text] [Related]
9. Paliperidone as a mood stabilizer: a pre-frontal cortex synaptoneurosomal proteomics comparison with lithium and valproic acid after chronic treatment reveals similarities in protein expression.
Corena-McLeod Mdel P; Oliveros A; Charlesworth C; Madden B; Liang YQ; Boules M; Shaw A; Williams K; Richelson E
Brain Res; 2008 Oct; 1233():8-19. PubMed ID: 18657526
[TBL] [Abstract][Full Text] [Related]
10. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
Leysen JE; Janssen PM; Megens AA; Schotte A
J Clin Psychiatry; 1994 May; 55 Suppl():5-12. PubMed ID: 7520908
[TBL] [Abstract][Full Text] [Related]
11. Effects of Risperidone and Paliperidone on Brain-Derived Neurotrophic Factor and N400 in First-Episode Schizophrenia.
Wu RQ; Lin CG; Zhang W; Lin XD; Chen XS; Chen C; Zhang LJ; Huang ZY; Chen GD; Xu DL; Lin ZG; Zhang MD
Chin Med J (Engl); 2018 Oct; 131(19):2297-2301. PubMed ID: 30246715
[TBL] [Abstract][Full Text] [Related]
12. Risperidone dose-dependently increases extracellular concentrations of serotonin in the rat frontal cortex: role of alpha 2-adrenoceptor antagonism.
Hertel P; Nomikos GG; Schilström B; Arborelius L; Svensson TH
Neuropsychopharmacology; 1997 Jul; 17(1):44-55. PubMed ID: 9194049
[TBL] [Abstract][Full Text] [Related]
13. A comparison of continuous subcutaneous paliperidone infusion and repeated subcutaneous injection of risperidone free-base in rats.
Marchese G; Pittau B; Casu G; Peddio G; Spada GP; Pira M; Deriu A; Portesani F; Pisu C; Lazzari P; Pani L
Eur Psychiatry; 2010 Mar; 25(2):92-100. PubMed ID: 19640686
[TBL] [Abstract][Full Text] [Related]
14. In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used.
Schotte A; Bonaventure P; Janssen PF; Leysen JE
Jpn J Pharmacol; 1995 Dec; 69(4):399-412. PubMed ID: 8786644
[TBL] [Abstract][Full Text] [Related]
15. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
Natesan S; Reckless GE; Nobrega JN; Fletcher PJ; Kapur S
Neuropsychopharmacology; 2006 Sep; 31(9):1854-63. PubMed ID: 16319908
[TBL] [Abstract][Full Text] [Related]
16. Risperidone inhibits 5-hydroxytryptaminergic neuronal activity in the dorsal raphe nucleus by local release of 5-hydroxytryptamine.
Hertel P; Nomikos GG; Svensson TH
Br J Pharmacol; 1997 Dec; 122(8):1639-46. PubMed ID: 9422809
[TBL] [Abstract][Full Text] [Related]
17. Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex.
Ohoyama K; Yamamura S; Hamaguchi T; Nakagawa M; Motomura E; Shiroyama T; Tanii H; Okada M
Eur J Pharmacol; 2011 Feb; 653(1-3):47-57. PubMed ID: 21147094
[TBL] [Abstract][Full Text] [Related]
18. Modeling of prolactin response following dopamine D
Taneja A; Vermeulen A; Huntjens DRH; Danhof M; De Lange ECM; Proost JH
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226628
[TBL] [Abstract][Full Text] [Related]
19. Effect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9-hydroxyrisperidone, pMHPG levels, and clinical improvement.
Yoshimura R; Nakamura J; Ueda N; Terao T
Int Clin Psychopharmacol; 2000 May; 15(3):175-80. PubMed ID: 10870876
[TBL] [Abstract][Full Text] [Related]
20. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial.
Kim SW; Chung YC; Lee YH; Lee JH; Kim SY; Bae KY; Kim JM; Shin IS; Yoon JS
Int Clin Psychopharmacol; 2012 Sep; 27(5):267-74. PubMed ID: 22809972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
